- Home
- XPEL vs IOVA Comparison
XPEL vs IOVA Comparison
Compare XPEL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- IOVA
- Stock Information
- Founded
- XPEL 1999
- IOVA 2007
- Country
- XPEL United States
- IOVA United States
- Employees
- XPEL N/A
- IOVA N/A
- Industry
- XPEL Industrial Specialties
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPEL Industrials
- IOVA Health Care
- Exchange
- XPEL Nasdaq
- IOVA Nasdaq
- Market Cap
- XPEL 984.3M
- IOVA 975.1M
- IPO Year
- XPEL N/A
- IOVA N/A
- Fundamental
- Price
- XPEL $34.92
- IOVA $1.97
- Analyst Decision
- XPEL
- IOVA Buy
- Analyst Count
- XPEL 0
- IOVA 11
- Target Price
- XPEL N/A
- IOVA $10.80
- AVG Volume (30 Days)
- XPEL 257.9K
- IOVA 12.5M
- Earning Date
- XPEL 11-05-2025
- IOVA 11-06-2025
- Dividend Yield
- XPEL N/A
- IOVA N/A
- EPS Growth
- XPEL 2.75
- IOVA N/A
- EPS
- XPEL 1.76
- IOVA N/A
- Revenue
- XPEL $448,897,000.00
- IOVA $241,525,000.00
- Revenue This Year
- XPEL $12.54
- IOVA $68.14
- Revenue Next Year
- XPEL $10.52
- IOVA $56.64
- P/E Ratio
- XPEL $20.20
- IOVA N/A
- Revenue Growth
- XPEL 9.96
- IOVA 636.99
- 52 Week Low
- XPEL $24.25
- IOVA $1.64
- 52 Week High
- XPEL $47.23
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- XPEL 49.79
- IOVA 39.33
- Support Level
- XPEL $35.42
- IOVA $2.10
- Resistance Level
- XPEL $37.71
- IOVA $2.35
- Average True Range (ATR)
- XPEL 0.99
- IOVA 0.12
- MACD
- XPEL 0.12
- IOVA -0.02
- Stochastic Oscillator
- XPEL 30.25
- IOVA 3.26
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.